Company Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease.
The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.
The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London.
INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Country | United States |
| IPO Date | Feb 4, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. Raymond Joseph Tesi M.D. |
Contact Details
Address: 225 NE Mizner Boulevard Boca Raton, Florida United States | |
| Website | https://www.inmunebio.com |
Stock Details
| Ticker Symbol | INMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001711754 |
| CUSIP Number | 45782T105 |
| ISIN Number | US45782T1051 |
| Employer ID | 47-5205835 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raymond Joseph Tesi M.D. | Co-Founder, President, Chief Executive Officer, Chief Medical Officer & Chairman |
| David J. Moss M.B.A. | Chief Financial Officer, Treasurer & Secretary |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Chief Scientific Officer & Chief Manufacturing Officer |
| Joshua S. Schoonover Esq. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | 8-A12B/A | [Amend] Filing |
| Dec 09, 2024 | 8-K | Current Report |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Nov 14, 2024 | 8-K | Current Report |